AT147270T - G-csf administration through the lung - Google Patents

G-csf administration through the lung

Info

Publication number
AT147270T
AT147270T AT92302239T AT92302239T AT147270T AT 147270 T AT147270 T AT 147270T AT 92302239 T AT92302239 T AT 92302239T AT 92302239 T AT92302239 T AT 92302239T AT 147270 T AT147270 T AT 147270T
Authority
AT
Austria
Prior art keywords
lung
csf administration
csf
administration
Prior art date
Application number
AT92302239T
Other languages
German (de)
Inventor
Robert M Platz
Mark A Winters
Colin G Pitt
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US66979291A priority Critical
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AT147270T publication Critical patent/AT147270T/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/193Colony stimulating factors [CSF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/885Immune response affecting drug
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/951Powders, granules or particles of specified mesh or particle size
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827Proteins from mammals or birds
    • Y10S530/838Marrow; spleen
AT92302239T 1991-03-15 1992-03-16 G-csf administration through the lung AT147270T (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US66979291A true 1991-03-15 1991-03-15

Publications (1)

Publication Number Publication Date
AT147270T true AT147270T (en) 1997-01-15

Family

ID=24687763

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92302239T AT147270T (en) 1991-03-15 1992-03-16 G-csf administration through the lung

Country Status (17)

Country Link
US (1) US5284656A (en)
EP (1) EP0505123B1 (en)
JP (1) JP3507486B2 (en)
CN (1) CN1066192A (en)
AT (1) AT147270T (en)
AU (1) AU643141B2 (en)
CA (1) CA2082951C (en)
DE (1) DE69216450T2 (en)
DK (1) DK0505123T3 (en)
ES (1) ES2097866T3 (en)
FI (1) FI106433B (en)
GR (1) GR3022663T3 (en)
IL (1) IL101235A (en)
NO (1) NO303716B1 (en)
NZ (1) NZ241954A (en)
WO (1) WO1992016192A1 (en)
ZA (1) ZA9201915B (en)

Families Citing this family (233)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3779221D1 (en) 1986-08-19 1992-06-25 Genentech Inc Device and dispersion for the intrapulmonal entering of polypeptide growth substances and cytokins.
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US6673335B1 (en) * 1992-07-08 2004-01-06 Nektar Therapeutics Compositions and methods for the pulmonary delivery of aerosolized medicaments
DE69332105T2 (en) * 1992-09-29 2003-03-06 Inhale Therapeutic Systems San Pulmonal delivery of active fragment of parathormon
US6012450A (en) * 1993-01-29 2000-01-11 Aradigm Corporation Intrapulmonary delivery of hematopoietic drug
US5354934A (en) * 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
US6169068B1 (en) 1993-02-12 2001-01-02 Avant Immunotherpeutics, Inc. Pulmonary administration of soluble complement receptor-1 (sCR1) and its derivatives
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
IS1796B (en) * 1993-06-24 2001-12-31 Ab Astra The polypeptide formulation for inhalation further comprising an enhancer compound
US6165976A (en) 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
US5747445A (en) * 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US6794357B1 (en) * 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US20010003739A1 (en) * 1993-06-24 2001-06-14 Astrazeneca Ab Systemic administration of a therapeutic preparation
WO1995023862A1 (en) * 1994-03-04 1995-09-08 Ludwig Institute For Cancer Research Animals with targeted gene disruption
CA2183577C (en) * 1994-03-07 2007-10-30 John S. Patton Methods and compositions for pulmonary delivery of insulin
US20030113273A1 (en) * 1996-06-17 2003-06-19 Patton John S. Methods and compositions for pulmonary delivery of insulin
KR100384353B1 (en) * 1994-05-18 2003-10-04 네크타르 테라퓨틱스 Methods and compositions for preparing dry powder formulations of interferon
US20030035778A1 (en) * 1997-07-14 2003-02-20 Robert Platz Methods and compositions for the dry powder formulation of interferon
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6124439A (en) * 1994-08-17 2000-09-26 The Rockefeller University OB polypeptide antibodies and method of making
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6124448A (en) * 1994-08-17 2000-09-26 The Rockfeller University Nucleic acid primers and probes for the mammalian OB gene
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
EE9700136A (en) 1994-12-22 1997-12-15 Astra Aktiebolag PTH parathyroid hormone containing formulation for inhalation
SE9404468D0 (en) * 1994-12-22 1994-12-22 Astra Ab Powder Formulations
NZ298169A (en) 1994-12-22 1999-09-29 Astra Ab Aerosol drug formulation; comprises hydrofluoroalkane propellant, medicament for inhalation and a surfactant
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
AU5710896A (en) * 1995-03-31 1996-10-16 Aradigm Corporation Intrapulmonary delivery of hematopoietic drug
US6936439B2 (en) * 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
AT357214T (en) 1996-12-30 2007-04-15 Battelle Memorial Institute Use of an uncapped anti-cancer to produce preparation for the treatment of neoplasms by inhalation
DE19733651A1 (en) * 1997-08-04 1999-02-18 Boehringer Ingelheim Pharma Aqueous aerosol preparations containing biologically active marrow molecules and processes for producing corresponding aerosols
PT1019022E (en) 1997-09-29 2003-08-29 Inhale Therapeutic Syst Perforated microparticles and methods of use
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US20060165606A1 (en) * 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6858706B2 (en) 1998-04-07 2005-02-22 St. Jude Children's Research Hospital Polypeptide comprising the amino acid of an N-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
US20030040467A1 (en) * 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
CN1810832B (en) 1998-10-23 2012-12-12 麒麟-安姆根有限公司 Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity
US6773911B1 (en) 1998-11-23 2004-08-10 Amgen Canada Inc. Apoptosis-inducing factor
KR20010113642A (en) 1999-01-13 2001-12-28 추후기재 A composition and method for the enhancement of the efficacy of drugs
US6500418B1 (en) * 1999-02-12 2002-12-31 The Washington University Stimulating neutrophil function to treat inflammatory bowel disease
JP5084984B2 (en) 1999-02-17 2012-11-28 シーエスエル、リミテッド Immunogenic complexes and methods related thereto
HU0104688A3 (en) * 1999-09-03 2004-07-28 Amgen Inc Thousand Oaks Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
KR100875483B1 (en) * 1999-11-19 2008-12-22 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 Vaccine Composition
EP1234031B1 (en) 1999-11-30 2017-03-15 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
JP2003519175A (en) * 1999-12-30 2003-06-17 カイロン コーポレイション Methods for pulmonary delivery of interleukin-2
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
US8404217B2 (en) * 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
PT1280520E (en) * 2000-05-10 2014-12-16 Novartis Ag Phospholipid-based powders for drug delivery
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
WO2002009674A2 (en) * 2000-07-28 2002-02-07 Inhale Therapeutic Systems, Inc. Methods and compositions to upregulate, redirect or limit immune responses to bioactive compounds
CA2417357A1 (en) 2000-08-08 2002-02-14 St. Jude Children's Research Hospital Group b streptococcus polypeptides nucleic acids and therapeutic compositions and vaccines thereof
ES2387546T3 (en) 2001-05-11 2012-09-25 Amgen Inc. Peptides and related molecules that bind to TALL-1
JP2005505540A (en) * 2001-08-27 2005-02-24 メディテック リサーチ リミテッドMediteck Research Limited Improved treatment protocol
US7332474B2 (en) * 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US6964761B1 (en) * 2001-12-12 2005-11-15 New York University Method of treating idiopathic pulmonary fibrosis with aerosolized IFN-γ
CA2468958C (en) * 2001-12-19 2012-07-03 Nektar Therapeutics Pulmonary delivery of aminoglycosides
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
EP1546184A4 (en) * 2002-07-16 2006-08-23 Univ South Florida Human immunosuppressive protein
AR040996A1 (en) 2002-08-19 2005-04-27 Coley Pharm Group Inc Immunostimulatory Nucleic Acids
CA2498651C (en) 2002-09-13 2011-08-30 Universite Laval Nucleoside triphosphate diphosphohydrolase and uses thereof
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
US7432351B1 (en) 2002-10-04 2008-10-07 Mayo Foundation For Medical Education And Research B7-H1 variants
US20060246104A1 (en) * 2003-04-16 2006-11-02 Massia Stephen P Stable rgd peptidomimetic composition
JP2007530440A (en) 2003-05-12 2007-11-01 アフィーマックス・インコーポレイテッドAffymax, Inc. Novel poly (ethylene glycol) modified compounds and uses thereof
BRPI0411166A (en) 2003-05-12 2006-07-18 Affymax Inc compound comprising a peptide moiety, a spacer moiety and a water soluble polymer moiety and a pharmaceutical composition comprising such a compound
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
EP2133362B1 (en) 2003-07-25 2012-04-18 Amgen, Inc Methods relating to LDCAM and CRTAM
US8338373B2 (en) * 2003-10-24 2012-12-25 Nora Therapeutics, Inc. Method for reducing the risk of spontaneous abortion in a human female subject
US20090226397A1 (en) 2003-10-24 2009-09-10 Nora Therapeutics, Inc. Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination
EP2198875A1 (en) * 2003-10-24 2010-06-23 Nora, LLC A method for reducing the likelihood of preterm labour in a subject in need thereof
JP5129927B2 (en) * 2003-11-04 2013-01-30 レツク・フアーマシユーテイカルズ・デー・デー Stable pharmaceutical composition comprising granulocyte-colony stimulating factor
KR101314461B1 (en) 2004-05-12 2013-10-07 더 브리검 앤드 우먼즈 하스피털, 인크. Use of gelsolin to treat infections
MX2007000216A (en) * 2004-07-08 2007-03-15 Amgen Inc Therapeutic peptides.
NZ553244A (en) 2004-07-18 2009-10-30 Csl Ltd Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
JP5017116B2 (en) 2004-09-24 2012-09-05 アムジエン・インコーポレーテツド Modified Fc molecule
EP3428191A1 (en) * 2004-10-06 2019-01-16 Mayo Foundation for Medical Education and Research B7-h1 and pd-1 in treatment of renal cell carcinoma
EP1814910A4 (en) * 2004-11-11 2009-04-29 Affymax Inc Novel peptides that bind to the erythropoietin receptor
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
WO2006119456A2 (en) * 2005-05-04 2006-11-09 University Of Vermont And State Agricultural College Methods and compositions for treating toxoplasma
US7919461B2 (en) * 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US20070031342A1 (en) * 2005-06-22 2007-02-08 Nektar Therapeutics Sustained release microparticles for pulmonary delivery
CN101365714A (en) 2005-07-01 2009-02-11 福赛特儿童口腔医院 Tuberculosis antigen detection assays and vaccines
CA2616607C (en) * 2005-07-27 2015-06-02 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US8623354B2 (en) * 2005-09-07 2014-01-07 Alchemia Oncology Pty Limited Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
WO2007088423A2 (en) * 2005-09-16 2007-08-09 Coley Pharmaceutical Gmbh Immunostimulatory single-stranded ribonucleic acid with phosphodiester backbone
WO2007031877A2 (en) * 2005-09-16 2007-03-22 Coley Pharmaceutical Gmbh Modulation of immunostimulatory properties of short interfering ribonucleic acid (sirna) by nucleotide modification
AU2005336519B2 (en) 2005-09-20 2012-05-10 New York University Method of treating pulmonary disease with interferons
TW200732350A (en) 2005-10-21 2007-09-01 Amgen Inc Methods for generating monovalent IgG
AU2006304886B2 (en) 2005-10-21 2012-04-12 Genzyme Corporation Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
TW200736277A (en) 2005-11-14 2007-10-01 Amgen Inc RANKL antibody-PTH/PTHrP chimeric molecules
US20070174128A1 (en) * 2005-11-30 2007-07-26 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging
US20070136092A1 (en) * 2005-11-30 2007-06-14 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging
US7827042B2 (en) * 2005-11-30 2010-11-02 The Invention Science Fund I, Inc Methods and systems related to transmission of nutraceutical associated information
US20070124219A1 (en) * 2005-11-30 2007-05-31 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems related to individualized nutraceutical selection and packaging
US8340944B2 (en) * 2005-11-30 2012-12-25 The Invention Science Fund I, Llc Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US20070124176A1 (en) * 2005-11-30 2007-05-31 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US20110145009A1 (en) * 2005-11-30 2011-06-16 Jung Edward K Y Methods and systems related to transmission of nutraceutical associatd information
US10296720B2 (en) 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
US8000981B2 (en) 2005-11-30 2011-08-16 The Invention Science Fund I, Llc Methods and systems related to receiving nutraceutical associated information
US20080114577A1 (en) * 2005-11-30 2008-05-15 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational methods and systems associated with nutraceutical related assays
US20080052114A1 (en) * 2005-11-30 2008-02-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems and methods related to nutraceuticals
US7974856B2 (en) 2005-11-30 2011-07-05 The Invention Science Fund I, Llc Computational systems and methods related to nutraceuticals
US8068991B2 (en) * 2005-11-30 2011-11-29 The Invention Science Fund I, Llc Systems and methods for transmitting pathogen related information and responding
US20080033763A1 (en) * 2005-11-30 2008-02-07 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems related to receiving nutraceutical associated information
US7927787B2 (en) * 2006-06-28 2011-04-19 The Invention Science Fund I, Llc Methods and systems for analysis of nutraceutical associated components
US20080004905A1 (en) * 2006-06-28 2008-01-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for analysis of nutraceutical associated components
US20100015642A1 (en) * 2006-01-05 2010-01-21 Kwon Eugene D B7-h1 and survivin in cancer
US20090215084A1 (en) * 2006-01-05 2009-08-27 Mayo Foundation For Medical Education And Research B7-h1 and b7-h4 in cancer
US20080044405A1 (en) * 2006-02-25 2008-02-21 President And Fellows Of Harvard College Noble metal complex-mediated immunosuppression
ES2651619T3 (en) 2006-03-15 2018-01-29 The Brigham And Women's Hospital, Inc. Use of gelsolin to treat multiple sclerosis and diagnose neurological diseases
DK2001496T3 (en) 2006-03-15 2017-09-18 The Brigham And Women's Hospital Inc Use of gelsolin for diagnostication and treatment of inflammation diseases
WO2007124361A2 (en) * 2006-04-20 2007-11-01 Mayo Foundation For Medical Education And Research Soluble b7-h1
EP2029157A4 (en) * 2006-05-19 2009-11-18 Georgia Tech Res Inst Abc transporter ligand
US20070289258A1 (en) * 2006-06-14 2007-12-20 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Individualized pharmaceutical selection and packaging
US8297028B2 (en) 2006-06-14 2012-10-30 The Invention Science Fund I, Llc Individualized pharmaceutical selection and packaging
US7981425B2 (en) * 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
EP2452683A3 (en) 2006-06-26 2012-08-22 Amgen Inc. Methods for treating atherosclerosis
DE102006030164A1 (en) * 2006-06-29 2008-01-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative powders
EP2049138A4 (en) * 2006-07-14 2011-11-09 Georgia Tech Res Inst Clc channel ligand
NZ575437A (en) 2006-09-27 2012-02-24 Coley Pharm Gmbh Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
WO2008088422A2 (en) * 2006-10-25 2008-07-24 Amgen Inc. Toxin peptide therapeutic agents
US7989173B2 (en) * 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
US20080206235A1 (en) * 2006-12-27 2008-08-28 Johns Hopkins University Compositions and methods for stimulating an immune response
WO2008116470A1 (en) * 2007-03-26 2008-10-02 Drugrecure Aps Enhancing pulmonary host defence via administration of granulocyte- colony stimulating factor
US8747872B2 (en) * 2007-05-02 2014-06-10 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
WO2008143892A1 (en) * 2007-05-18 2008-11-27 New York University Method of treating tuberculosis with interferons
US9200287B2 (en) * 2007-05-18 2015-12-01 Adiutide Pharmaceuticals Gmbh Phosphate-modified oligonucleotide analogs with enhanced immunostimulatory activity
US8105572B2 (en) * 2007-05-18 2012-01-31 New York University Method of treating tuberculosis with interferons
US8420779B2 (en) * 2007-05-22 2013-04-16 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
EP2170946A2 (en) * 2007-07-13 2010-04-07 The Johns Hopkins University B7-dc variants
ES2513716T3 (en) 2007-07-26 2014-10-27 Amgen, Inc Modified lecithin-cholesteros acitransferase enzymes
BRPI0815280A2 (en) 2007-08-27 2018-11-27 Biogenerix Ag medicament comprising an aqueous liquid formulation of g-csf, receptacle for the administration of liquid medicaments, syringe or ampoule, kit for parenteral administration of g-csf
CN101820908A (en) * 2007-10-09 2010-09-01 科利制药公司 The immune stimulatory oligonucleotide analogs that comprises modified sugar moieties
PT2207787E (en) 2007-11-06 2015-02-17 Adiutide Pharmaceuticals Gmbh Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
US8236753B2 (en) * 2007-12-10 2012-08-07 The Brigham And Women's Hospital, Inc. RAP variants for drug delivery and methods of use thereof
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
PT2708603T (en) 2008-01-25 2017-07-20 The Brigham And Women`S Hospital Inc Diagnostic and therapeutic uses of gelsolin in renal failure
WO2009111315A2 (en) * 2008-02-29 2009-09-11 Mayo Foundation For Medical Education And Research Methods for reducing granulomatous inflammation
US8475785B2 (en) 2008-03-03 2013-07-02 The University Of Miami Allogeneic cancer cell-based immunotherapy
KR20110017356A (en) 2008-03-20 2011-02-21 유니버시티 오브 마이애미 Heat shock protein gp96 vaccination and methods of using same
US20110171168A1 (en) * 2008-05-13 2011-07-14 Nora Therapeutics, Inc. Human g-csf analogs and methods of making and using thereof
AU2009274571A1 (en) * 2008-07-23 2010-01-28 Massachusetts Institute Of Technology Activation of histone deacetylase 1 (HDAC1) protects against DNA damage and increases neuronal survival
WO2010014222A1 (en) 2008-07-30 2010-02-04 Dana-Farber Cancer Institute, Inc. Compositions for detecting cell death and methods of use thereof
US10457639B2 (en) 2008-08-15 2019-10-29 Georgetown University Fluorescent regulators of RASSF1A expression and human cancer cell proliferation
EP2367812B1 (en) * 2008-08-22 2015-09-16 Sanofi [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4trifluoromethoxy-1h-indol-3-yl]methanone as an inhibitor of mast cell tryptase
EP2927240A1 (en) 2008-08-25 2015-10-07 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
US20110195068A1 (en) * 2008-08-25 2011-08-11 Solomon Langermann Pd-1 antagonists and methods of use thereof
EP2949752B1 (en) 2008-09-22 2017-12-20 RXi Pharmaceuticals Corporation Reduced size self-delivering rnai compounds
US8962026B2 (en) * 2008-09-26 2015-02-24 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
US8147847B2 (en) * 2008-10-21 2012-04-03 International Vaccine Institute Shigella protein antigens and methods
AU2009314704A1 (en) 2008-11-13 2010-05-20 Instituto De Medicina Molecular Foxp3+ natural kiler T-cells and the treatment of immune related diseases
CA2743904A1 (en) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
US8628762B2 (en) 2008-12-10 2014-01-14 Icahn School Of Medicine At Mount Sinai T-helper cell type 17 lineage-specific adjuvants, compositions and methods
TW201034675A (en) 2008-12-18 2010-10-01 Sanofi Aventis Method for treating macular degeneration
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US10011906B2 (en) 2009-03-31 2018-07-03 Beohringer Ingelheim International Gmbh Method for coating a surface of a component
US9265910B2 (en) 2009-05-18 2016-02-23 Boehringer Ingelheim International Gmbh Adapter, inhalation device, and nebulizer
BRPI1014031A2 (en) 2009-06-16 2018-02-20 Univ Michigan Regents nanoemulsion vaccines
WO2011014257A1 (en) 2009-07-31 2011-02-03 The General Hospital Corporation Approaches to treat cancer using hb-egf inhibitors such as myrsinoic acid a
KR20120089259A (en) 2009-08-03 2012-08-09 유니버시티 오브 마이애미 Method for in vivo expansion of t regulatory cells
AU2010286351A1 (en) 2009-08-31 2012-03-15 Amplimmune, Inc. B7-H4 fusion proteins and methods of use thereof
EP2493468A1 (en) 2009-10-30 2012-09-05 Sanofi Amino-benzoic acid derivatives for use in the treatment of dihydrogenase-related disorders
WO2011064164A1 (en) 2009-11-25 2011-06-03 Boehringer Ingelheim International Gmbh Nebulizer
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
JP5658268B2 (en) 2009-11-25 2015-01-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Nebulizer
CN102791702A (en) 2009-12-23 2012-11-21 赛诺菲 Prodrugs of [4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1H-pyrrolo-pyridin-yl)-methanones and synthesis thereof
WO2011078984A1 (en) 2009-12-23 2011-06-30 Sanofi [4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1h-pyrrolo-pyridin-yl)-methanones and synthesis thereof
FR2955324A1 (en) 2010-01-15 2011-07-22 Sanofi Aventis Disubstituted 4- (5-aminomethyl-phenyl) -piperidin-1-yl] -1h-indol-3-yl] -methanones
EP2550000A4 (en) 2010-03-24 2014-03-26 Advirna Inc Reduced size self-delivering rnai compounds
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
US9943654B2 (en) 2010-06-24 2018-04-17 Boehringer Ingelheim International Gmbh Nebulizer
WO2012006506A1 (en) 2010-07-09 2012-01-12 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy
AU2012228990B2 (en) 2011-03-16 2017-04-06 Amgen Inc. Potent and selective inhibitors of Nav1.3 and Nav1.7
WO2012134975A1 (en) 2011-03-28 2012-10-04 St. Jude Children's Research Hospital Methods and compositions employing immunogenic fusion proteins
EP2694220B1 (en) 2011-04-01 2020-05-06 Boehringer Ingelheim International GmbH Medical device comprising a container
CA2834548A1 (en) 2011-04-28 2012-11-01 The Broad Institute, Inc. Inhibitors of histone deacetylase
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
TR201901856T4 (en) 2011-07-22 2019-03-21 Massachusetts Inst Technology Class II histone deacetylases (HDACs) activators and their uses.
WO2013021279A2 (en) 2011-08-10 2013-02-14 Lfb Biotechnologies Highly galactosylated antibodies
US20130236484A1 (en) 2012-03-08 2013-09-12 Detectogen Inc. Leishmaniasis antigen detection assays and vaccines
TW201400499A (en) 2012-03-12 2014-01-01 Revo Biolog Inc The use of antithrombin in the treatment of pre-eclampsia
WO2013152894A1 (en) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Atomiser with coding means
US20160067347A1 (en) 2012-12-20 2016-03-10 Amgen Inc. Apj receptor agonists and uses thereof
WO2014100438A1 (en) 2012-12-20 2014-06-26 The Broad Institute, Inc. Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
WO2014165277A2 (en) 2013-03-12 2014-10-09 Amgen Inc. POTENT AND SELECTIVE INHIBITORS OF Nav1.7
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2014168721A2 (en) 2013-04-12 2014-10-16 Tufts Medical Center Methods and systems for designing and/or characterizing soluble lipidated ligand agents
EP2835146B1 (en) 2013-08-09 2020-09-30 Boehringer Ingelheim International GmbH Nebulizer
EP3030298B1 (en) 2013-08-09 2017-10-11 Boehringer Ingelheim International GmbH Nebulizer
DK3041958T3 (en) 2013-09-04 2020-03-09 Cold Spring Harbor Laboratory Reducing nonsense-mediated mrna degradation
EP3052131B1 (en) 2013-10-01 2018-12-05 Mayo Foundation for Medical Education and Research Methods for treating cancer in patients with elevated levels of bim
WO2015057724A1 (en) 2013-10-14 2015-04-23 Nora Therapeutics, Inc. Use of g-csf for treating or preventing villitis of unknown etiology in a human female
JP6306700B2 (en) 2013-11-01 2018-04-04 ユニバーシティ オブ オスロUniversity of Oslo Modified albumin and use thereof
US20160263205A1 (en) 2013-11-15 2016-09-15 Oslo Universitetssykehus Hf Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
WO2015167567A1 (en) 2014-05-01 2015-11-05 Charlesson Llc Stat3 inhibitors for treatment of hyperglycemia and impaired spatial vision
WO2015169431A2 (en) 2014-05-07 2015-11-12 Boehringer Ingelheim International Gmbh Nebulizer, indicator device and container
EP3139984A1 (en) 2014-05-07 2017-03-15 Boehringer Ingelheim International GmbH Nebulizer
EA032850B1 (en) 2014-05-07 2019-07-31 Бёрингер Ингельхайм Интернациональ Гмбх Container, nebulizer and method of making a container
US10302653B2 (en) 2014-05-22 2019-05-28 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti B7-H1 antibodies
EP3155002B1 (en) 2014-06-10 2019-11-27 Amgen Inc. Apelin polypeptides
US10517875B2 (en) 2014-07-23 2019-12-31 Mayo Foundation for Medical Engineering and Research Targeting DNA-PKcs and B7-H1 to treat cancer
EP3204039A4 (en) 2014-10-10 2018-05-30 The Regents Of The University Of Michigan Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
WO2016080853A1 (en) 2014-11-21 2016-05-26 Bsim2 – Biomolecular Simulations Lda 2-thioxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof
US9440953B2 (en) 2014-12-19 2016-09-13 OncoArendi Therapeutics Sp. z o.o. Substituted amino triazoles useful as acidic mammalian chitinase inhibitors
PL410665A1 (en) 2014-12-29 2016-07-04 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Arginase inhibitors and their therapeutical applications
WO2016168568A1 (en) 2015-04-15 2016-10-20 Revolution Medicines, Inc. Derivatives of amphotericin b
WO2016203402A1 (en) 2015-06-15 2016-12-22 Bsim2 – Biomolecular Simulations Lda Bis-furan derivatives as transthyretin (ttr) stabilizers and amyloid inhibitors for the treatment of familial amyloid polyneuropathy (fap)
PL415078A1 (en) 2015-09-04 2017-03-13 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Substituted amino triazoles, suitable as acidic mammalian chitinase inhibitors
PL417066A1 (en) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Arginase inhibitors and their therapeutical applications
WO2018080573A1 (en) 2016-10-28 2018-05-03 Massachusetts Institute Of Technology Crispr/cas global regulator screening platform
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
WO2019048936A1 (en) 2017-09-07 2019-03-14 University Of Oslo Vaccine molecules
WO2019048928A1 (en) 2017-09-07 2019-03-14 University Of Oslo Vaccine molecules

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0144200B2 (en) * 1984-07-25 1989-09-26 Chugai Pharmaceutical Co Ltd
JPS62207226A (en) * 1986-03-07 1987-09-11 Sumitomo Pharmaceut Co Ltd Pharmaceutical for nasotracheal administration
JPH0618781B2 (en) * 1986-10-18 1994-03-16 中外製薬株式会社 Infectious disease treatment agent
US4961926A (en) * 1987-11-19 1990-10-09 Sloan-Kettering Institute For Cancer Research Methods for prevention and treatment of mucositis with granulocyte colony stimulating factor
AU7908791A (en) * 1990-05-08 1991-11-27 Liposome Technology, Inc. Direct spray-dried drug/lipid powder composition

Also Published As

Publication number Publication date
GR3022663T3 (en) 1997-05-31
FI106433B1 (en)
IL101235D0 (en) 1992-11-15
FI925163D0 (en)
FI925163A (en) 1992-11-13
AU643141B2 (en) 1993-11-04
US5284656A (en) 1994-02-08
DE69216450D1 (en) 1997-02-20
CA2082951C (en) 1999-12-21
CN1066192A (en) 1992-11-18
FI106433B (en) 2001-02-15
NZ241954A (en) 1994-01-26
NO924413D0 (en) 1992-11-16
EP0505123A1 (en) 1992-09-23
JPH05507944A (en) 1993-11-11
EP0505123B1 (en) 1997-01-08
IL101235A (en) 1998-10-30
FI925163A0 (en) 1992-11-13
ES2097866T3 (en) 1997-04-16
AU1747692A (en) 1992-10-21
DE69216450T2 (en) 1997-04-30
NO924413L (en) 1993-01-14
JP3507486B2 (en) 2004-03-15
WO1992016192A1 (en) 1992-10-01
ZA9201915B (en) 1993-04-28
NO303716B1 (en) 1998-08-24
DK0505123T3 (en) 1997-06-30

Similar Documents

Publication Publication Date Title
DE69220618T2 (en) Aerosol inhaler
DE69219145T2 (en) Syringe
DE69218592T2 (en) Syringe
DK0606351T3 (en) Apparatus for securing the lung condition
DE69313510D1 (en) Delivery catheter
DE69229544T2 (en) Representation of the shape of the airway
DE69126311D1 (en) Therapeutic compositions based on ribozyms
DE69110785D1 (en) Anesthetic vaporizer.
DE69222933T2 (en) cholangiography catheter
DE69124516D1 (en) catheter
DE69228610T2 (en) Toy construction set
FI96823C (en) The fire-fighting unit
DK0616525T3 (en) medications
DE69107835T2 (en) Therapeutic pillow.
AT130771T (en) Inhalator.
GB2265552B (en) Inhaler
FI922746A0 (en) Nya sulphonamider.
FI923515A0 (en) Nya herbicider.
DE3875126T2 (en) Laser-resistant endotracheal tube.
FI934332A0 (en) Nya proteaser
FI925549A (en) Nya azaheterocyclylmethyl chromaner
FI935093A (en) Hypodermic naolar
FR2672499B1 (en) Inhalation apparatus.
FI934925A (en) Nya immunosuppressiva foereningar
GR3015939T3 (en) Pharmaceutical composition.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee